select.mtd.pop

Select the maximum tolerated dose (MTD) when the single-agent trial is completed

The primary goal of phase I clinical trials is to find the maximum tolerated dose (MTD). To reach this objective, we introduce a new design for phase I clinical trials, the posterior predictive (PoP) design. The PoP design is an innovative model-assisted design that is as simply as the conventional algorithmic designs as its decision rules can be pre-tabulated prior to the onset of trial, but is of more flexibility of selecting diverse target toxicity rates and cohort sizes. The PoP design has desirable properties, such as coherence and consistency. Moreover, the PoP design provides better empirical performance than the BOIN and Keyboard design with respect to high average probabilities of choosing the MTD and slightly lower risk of treating patients at subtherapeutic or overly toxic doses.

Xinying Fang

PoPdesign

Posterior Predictive (PoP) Design for Phase I Clinical Trials

Chenqi Fu

Shouhao Zhou

select.mtd.pop function

<dl><dt>target</dt>
<dd>the target DLT rate</dd>
<dt>n.pts</dt>
<dd>a vector containing the number of patients treated at each dose level</dd>
<dt>n.tox</dt>
<dd>a vector containing the number of patients who experienced dose-limiting
toxicity at each dose level</dd></dl>

Arguments

Maximum tolerated dose (MTD) selection for single-agent trials — select.mtd.pop

<dl>

<dt>target</dt>
<dd>the target DLT rate</dd>


<dt>n.pts</dt>
<dd>a vector containing the number of patients treated at each dose level</dd>


<dt>n.tox</dt>
<dd>a vector containing the number of patients who experienced dose-limiting
toxicity at each dose level</dd>

</dl>

select.mtd.pop: Maximum tolerated dose (MTD) selection for single-agent trials

Description

Usage

Value

Arguments

References

Examples